Relationship of Viral Resistance Development to CD4 Monitoring Alone or With Viral Load Monitoring
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00434070|
Recruitment Status : Completed
First Posted : February 12, 2007
Last Update Posted : January 15, 2019
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:
National Institutes of Health Clinical Center (CC)
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Primary Completion Date :||No date given|
|Study Completion Date :||February 7, 2013|
Akileswaran C, Lurie MN, Flanigan TP, Mayer KH. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis. 2005 Aug 1;41(3):376-85. Epub 2005 Jun 30. Review.
Deeks SG, Grant RM. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. Antivir Ther. 1999;4 Suppl 3:7-11. Review.
Weiss L, Burgard M, Cahen YD, Chaix ML, Laureillard D, Gilquin J, Piketty C, Viard JP, Kazatchkine MD, Girard PM, Rouzioux C. Immunological and virological features of HIV-infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor-based therapy. HIV Med. 2002 Jan;3(1):12-20.